Migraine Management: Standard Care First, Selank and DSIP Only for Comorbid Stress and Sleep

The most important point is scientific: CGRP (calcitonin gene-related peptide) is a driver of migraine, which is precisely why leading migraine drugs are CGRP antagonists — monoclonal antibodies and gepants that block it. That means administering a CGRP peptide would be expected to provoke or worsen migraine, and no CGRP-agonist peptide belongs in a migraine stack. Effective, evidence-based care is the real answer: CGRP monoclonal antibodies or gepants for prevention, triptans or gepants for acute attacks, and, where appropriate, other established preventives a neurologist selects, all layered on consistent sleep, hydration, regular meals, and identification of personal triggers. The only place research peptides enter honestly is at the margins — selank has been explored for anxiety and DSIP for sleep regulation, so if stress or poor sleep are migraine-aggravating comorbidities, they are sometimes discussed as speculative adjuncts. Neither has validated human dosing for migraine or its comorbidities, neither is an approved therapy, and neither should displace proven migraine treatment; any use should be medically supervised.